Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Operating Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Operating Expenses for 4 consecutive years, with -$509000.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses fell 197.51% to -$509000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$894000.0 through Dec 2025, down 127.28% year-over-year, with the annual reading at -$894000.0 for FY2025, 127.28% down from the prior year.
  • Other Operating Expenses for Q4 2025 was -$509000.0 at Orchestra BioMed Holdings, up from -$515000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $1.2 million in Q3 2023, with the low at -$601000.0 in Q1 2022.
  • Average Other Operating Expenses over 4 years is $238625.0, with a median of $122000.0 recorded in 2022.
  • Peak annual rise in Other Operating Expenses hit 661.86% in 2023, while the deepest fall reached 532.05% in 2023.
  • Over 4 years, Other Operating Expenses stood at $78000.0 in 2022, then crashed by 532.05% to -$337000.0 in 2023, then surged by 254.9% to $522000.0 in 2024, then crashed by 197.51% to -$509000.0 in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$509000.0, -$515000.0, and -$36000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.